Claims for Patent: 10,597,384

Summary for Patent: 10,597,384

Title:	Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl) benzoic acid
Abstract:	The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methypyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.
Inventor(s):	Keshavarz-Shokri; Ali (San Diego, CA), Zhang; Beili (San Diego, CA), Krawiec; Mariusz (Marlborough, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:	15/807,663
Patent Claims:	1. A crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid having a monoclinic crystal system, a P2.sub.1/n space group, and the following unit cell dimensions: a=4.9626 (7) .ANG. .alpha.=90.degree. b=12.2994 (18) .ANG. .beta.=93.938 (9).degree. c=33.075 (4) .ANG. .gamma.=90.degree.. 2. A pharmaceutical composition comprising the crystal form of claim 1 and a pharmaceutically acceptable carrier. 3. A method of treating cystic fibrosis in a patient comprising administering the patient an effective amount of the crystal form of claim 1. 4. The method of claim 3, wherein the patient is homozygous for the .DELTA.F508 CFTR mutation.